Fig. 7.

Esomeprazole ameliorates the preeclampsia symptoms caused by L‐NAME. (a) Plot showing the SBP of control, L-NAME-treated, or L-NAME + esomeprazole-treated mice were measured. (b) Plot showing the urinary protein concentrations of the control, L-NAME-treated, or L-NAME + esomeprazole-treated mice were determined. (c) The sFLT-1 concentrations in the serum of control, L-NAME, or L-NAME + esomeprazole-treated mice were determined at GD18.5 using ELISA. (d, d′, d″) Histological analysis of the placentas of control, L-NAME-treated, or L-NAME + esomeprazole-treated mice using H&E staining. (e, e′, e″) Fibrosis in the placentas of control, L-NAME-treated, or L-NAME + esomeprazole-treated mice were measured using Trichrome Masson staining. A blue color in the square indicates collagen deposition, N = 3 mice per group, *P < 0.05, **P < 0.01